Clinical outcomes and immunological features of COVID-19 patients receiving B-cell depletion therapy during the Omicron era

References

• Salles G, Barrett M, Foa R, et al. Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience. Adv Ther. 2017;34(10):2232–2273. doi: 10.1007/s12325-017-0612-x.
   PubMed Web of Science ®Google Scholar
• Kaegi C, Wuest B, Schreiner J, et al. Systematic review of safety and efficacy of rituximab in treating immune-mediated disorders. Front Immunol. 2019;10:1990. doi: 10.3389/fimmu.2019.01990.
   PubMed Web of Science ®Google Scholar
• Sacco KA, Abraham RS. Consequences of B-cell-depleting therapy: hypogammaglobulinemia and impaired B-cell reconstitution. Immunotherapy. 2018;10(8):713–728. doi: 10.2217/imt-2017-0178.
   PubMed Web of Science ®Google Scholar
• Barmettler S, Ong MS, Farmer JR, et al. Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia. JAMA Netw Open. 2018;1(7):e184169. doi: 10.1001/jamanetworkopen.2018.4169.
   PubMed Web of Science ®Google Scholar
• Aviv R, Weber A, Anzum T, et al. Prolonged coronavirus disease 2019 in a patient with rheumatoid arthritis on rituximab therapy. J Infect Dis. 2021;224(3):557–559. doi: 10.1093/infdis/jiab248.
   PubMed Web of Science ®Google Scholar
• Morishita M, Suzuki M, Matsunaga A, et al. Prolonged SARS-CoV-2 infection associated with long-term corticosteroid use in a patient with impaired B-cell immunity. J Infect Chemother. 2022;28(7):971–974. doi: 10.1016/j.jiac.2022.02.006.
   PubMed Web of Science ®Google Scholar
• Bektaş M, Özdemir G. Protracted or recurrent COVID-19 associated cytokine storm in a patient with chronic lymphocytic leukemia receiving rituximab-based chemotherapy. Clin Immunol. 2022;236:108936. doi: 10.1016/j.clim.2022.108936.
   PubMed Web of Science ®Google Scholar
• Thornton CS, Huntley K, Berenger BM, et al. Prolonged SARS-CoV-2 infection following rituximab treatment: clinical course and response to therapeutic interventions correlated with quantitative viral cultures and cycle threshold values. Antimicrob Resist Infect Control. 2022;11(1):28. doi: 10.1186/s13756-022-01067-1.
   PubMed Web of Science ®Google Scholar
• Avouac J, Drumez E, Hachulla E, et al. COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study. Lancet Rheumatol. 2021;3(6):e419–e426. doi: 10.1016/S2665-9913(21)00059-X.
   PubMedGoogle Scholar
• Regierer AC, Hasseli R, Schafer M, et al. TNFi is associated with positive outcome, but JAKi and rituximab are associated with negative outcome of SARS-CoV-2 infection in patients with RMD. RMD Open. 2021;7(3):e001896. doi: 10.1136/rmdopen-2021-001896.
   PubMed Web of Science ®Google Scholar
• Boekel L, Wolbink GJ. Rituximab during the COVID-19 pandemic: time to discuss treatment options with patients. Lancet Rheumatol. 2022;4(3):e154–e155. doi: 10.1016/S2665-9913(21)00418-5.
   PubMedGoogle Scholar
• Wang C, Liu B, Zhang S, et al. Differences in incidence and fatality of COVID-19 by SARS-CoV-2 omicron variant versus Delta variant in relation to vaccine coverage: a world-wide review. J Med Virol. 2023;95(1):e28118. doi: 10.1002/jmv.28118.
   PubMed Web of Science ®Google Scholar
• Habek M, Jakob Brecl G, Basic Kes V, et al. Humoral immune response in convalescent COVID-19 people with multiple sclerosis treated with high-efficacy disease-modifying therapies: a multicenter, case-control study. J Neuroimmunol. 2021;359:577696. doi: 10.1016/j.jneuroim.2021.577696.
   PubMed Web of Science ®Google Scholar
• Zabalza A, Cardenas-Robledo S, Tagliani P, et al. COVID-19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response. Eur J Neurol. 2021;28(10):3384–3395. doi: 10.1111/ene.14690.
   PubMed Web of Science ®Google Scholar
• Damato V, Spagni G, Monte G, et al. Immunological response after SARS-CoV-2 infection and mRNA vaccines in patients with myasthenia gravis treated with rituximab. Neuromuscul Disord. 2023;33(3):288–294. doi: 10.1016/j.nmd.2023.02.005.
   PubMed Web of Science ®Google Scholar
• Chen AT, Altschuler K, Zhan SH, et al. COVID-19 CG enables SARS-CoV-2 mutation and lineage tracking by locations and dates of interest. Elife. 2021;10:e63409. doi: 10.7554/eLife.63409.
   PubMed Web of Science ®Google Scholar
• Abu-Raddad LJ, Chemaitelly H, Ayoub HH, et al. Association of prior SARS-CoV-2 infection with risk of breakthrough infection following mRNA vaccination in Qatar. JAMA. 2021;326(19):1930–1939. doi: 10.1001/jama.2021.19623.
   PubMed Web of Science ®Google Scholar
• Moor MB, Suter-Riniker F, Horn MP, et al. Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study. Lancet Rheumatol. 2021;3(11):e789–e797. doi: 10.1016/S2665-9913(21)00251-4.
   PubMedGoogle Scholar
• COVID-19 Treatment Guidelines Panel. Coronavirus Disease. (COVID-19) Treatment Guidelines. National Institutes of Health. 2019 [cited 2023 Feb 1]. https://www.covid19treatmentguidelines.nih.gov/.
   Google Scholar
• World Health Organization. International guidelines for certification and classification (coding) of COVID-19 as cause of death. 2023 [cited 2023 Feb 1]. https://www.who.int/publications/m/item/international-guidelines-for-certification-and-classification-(coding)-of-covid-19-as-cause-of-death
   Google Scholar
• Kang CK, Shin HM, Choe PG, et al. Broad humoral and cellular immunity elicited by one-dose mRNA vaccination 18 months after SARS-CoV-2 infection. BMC Med. 2022;20(1):181. doi: 10.1186/s12916-022-02383-4.
   PubMed Web of Science ®Google Scholar
• Kang CK, Kim M, Hong J, et al. Distinct immune response at 1 year post-COVID-19 according to disease severity. Front Immunol. 2022;13:830433. doi: 10.3389/fimmu.2022.830433.
   PubMed Web of Science ®Google Scholar
• Choe PG, Hong J, Park J, et al. Persistent antibody responses up to 18 months after mild SARS-CoV-2 infection. J Infect Dis. 2022;226(7):1224–1230. doi: 10.1093/infdis/jiac099.
   PubMed Web of Science ®Google Scholar
• Kang CK, Kim HR, Song KH, et al. Cell-Mediated immunogenicity of influenza vaccination in patients with cancer receiving immune checkpoint inhibitors. J Infect Dis. 2020;222(11):1902–1909. doi: 10.1093/infdis/jiaa291.
   PubMed Web of Science ®Google Scholar
• Kang CK, Han GC, Kim M, et al. Aberrant hyperactivation of cytotoxic T-cell as a potential determinant of COVID-19 severity. Int J Infect Dis. 2020;97:313–321. doi: 10.1016/j.ijid.2020.05.106.
   PubMed Web of Science ®Google Scholar
• Jefferson T, Spencer EA, Conly JM, et al. Viral cultures, cycle threshold values and viral load estimation for assessing SARS-CoV-2 infectiousness in haematopoietic stem cell and solid organ transplant patients: a systematic review. J Hosp Infect. 2023;132:62–72. doi: 10.1016/j.jhin.2022.11.018.
   PubMed Web of Science ®Google Scholar
• MacKenna B, Kennedy NA, Mehrkar A, et al. Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform. Lancet Rheumatol. 2022;4(7):e490–e506. doi: 10.1016/S2665-9913(22)00098-4.
   PubMedGoogle Scholar
• Dulery R, Lamure S, Delord M, et al. Prolonged in-hospital stay and higher mortality after covid-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapy. Am J Hematol. 2021;96(8):934–944. doi: 10.1002/ajh.26209.
   PubMed Web of Science ®Google Scholar
• Nyberg T, Ferguson NM, Nash SG, et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and Delta (B.1.617.2) variants in England: a cohort study. Lancet. 2022;399(10332):1303–1312. doi: 10.1016/S0140-6736(22)00462-7.
   PubMed Web of Science ®Google Scholar
• Lee CM, Choe PG, Kang CK, et al. Low humoral and cellular immune responses early after breakthrough infection may contribute to severe COVID-19. Front Immunol. 2023;14:1106664. doi: 10.3389/fimmu.2023.1106664.
   PubMedGoogle Scholar
• Alfonso-Dunn R, Lin J, Kirschner V, et al. Strong T-cell activation in response to COVID-19 vaccination in multiple sclerosis patients receiving B-cell depleting therapies. Front Immunol. 2022;13:926318. doi: 10.3389/fimmu.2022.926318.
   PubMed Web of Science ®Google Scholar
• Apostolidis SA, Kakara M, Painter MM, et al. Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. Nat Med. 2021;27(11):1990–2001. doi: 10.1038/s41591-021-01507-2.
   PubMed Web of Science ®Google Scholar
• Atanackovic D, Luetkens T, Omili D, et al. Vaccine-induced T-cell responses against SARS-CoV-2 and its omicron variant in patients with B cell-depleted lymphoma after CART therapy. Blood. 2022;140(2):152–156. doi: 10.1182/blood.2022016175.
   PubMed Web of Science ®Google Scholar
• Nissimov N, Hajiyeva Z, Torke S, et al. B cells reappear less mature and more activated after their anti-CD20-mediated depletion in multiple sclerosis. Proc Natl Acad Sci U S A. 2020;117(41):25690–25699. doi: 10.1073/pnas.2012249117.
   PubMed Web of Science ®Google Scholar
• Moss P. The T cell immune response against SARS-CoV-2. Nat Immunol. 2022;23(2):186–193. doi: 10.1038/s41590-021-01122-w.
   PubMed Web of Science ®Google Scholar